Evaluation of Respiratory Muscle Sarcopenia in Obstructive Sleep Apnea Syndrome (RMS-OSAS)

Tarsus University

Status: Invitation-only

Conditions: Obstructive Sleep Apnea (OSAS)

Study type: Observational

Funder types: Other

Identifiers

NCT06783998

2025/01

Details and patient eligibility

About

OSAS is a disease characterized by repeated interruptions and restarts of breathing during sleep. Respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. Decreased respiratory effort is an important indicator of OSAS. Age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. If OSAS is left untreated, it leads to cardiovascular diseases, dementia, Alzheimer's and even death in early adulthood. In recent years, studies have shown that continuous positive airway pressure (CPAP), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. There is no research in the literature on the evaluation of respiratory muscle sarcopenia in OSAS patients.

This study aims to evaluate respiratory muscle sarcopenia in OSAS based on a concrete value reflecting respiratory muscle strength and/or volume.

Full description

In the study, respiratory muscle sarcopenia will be evaluated in OSAS patients. It will be evaluated whether the expiratory pressure value, peek flow meter value and 6-minute walking distance are predictors of respiratory sarcopenia for OSAS.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with normal-mild-medium-severe OSAS
• 18 years and above
• Turkish speaking patients will be included.

Exclusion criteria

• Pregnancy,

  • Latent autoimmune diabetes,
  • Chronic renal failure,
  • Active or serious infections,
  • Liver failure,
  • Recent major cardiovascular events,
  • Unstable angina, heart failure (NYHA III-IV),
  • Patients with neurological or musculoskeletal disorders that create limitations in walking and performing tests

Trial design

150 participants in 1 patient group

OSAS

Description:

Turkish-speaking patients diagnosed with normal-mild-moderate-severe OSAS, aged 18 and over, will be included.